Advertisement
Advertisement
ABSI
Absci Corporation Common Stock
8.93
USDSponsored
+0.63
+7.59%
Aug 07, 15:59 UTC -4
Closed
After-Market
8.94
+0.01
+0.12%
ABSI Earnings Reports
Positive Surprise Ratio
ABSI beat 4 of 20 last estimates.
20%
Next Report
In 2 Days
Date of Next Report
Aug 11, 2026
Estimate for Q2 26 (Revenue/ EPS)
$1.24M
/-$0.20
Implied change from Q1 26 (Revenue/ EPS)
+475.06%
/+5.26%
Implied change from Q2 25 (Revenue/ EPS)
+108.50%
/-16.67%
Absci Corporation Common Stock earnings per share and revenue
On May 07, 2026, ABSI reported earnings of -0.19 USD per share (EPS) for Q1 26, beating the estimate of -0.21 USD, resulting in a 11.30% surprise. Revenue reached 215.00 thousand, compared to an expected 1.58 million, with a -86.40% difference. The market reacted with a +2.61% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 9 analysts forecast an EPS of -0.20 USD, with revenue projected to reach 1.24 million USD, implying an increase of 5.26% EPS, and increase of 475.06% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
ANI Pharmaceuticals, Inc.
Report Date
Aug 07, 2026 For Q2 26
Estimate
$2.09
Actual
$2.21
Surprise
+5.69%
Monte Rosa Therapeutics, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.39
Actual
-$0.43
Surprise
-9.58%
CytomX Therapeutics, Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.07
Actual
-$0.09
Surprise
-13.78%
Prime Medicine, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.26
Actual
-$0.24
Surprise
+8.57%
Prothena Corporation plc Ordinary Shares
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.39
Actual
-$0.32
Surprise
+19.76%
Ocugen, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.05
Actual
-$0.07
Surprise
-26.35%
X4 Pharmaceuticals, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.18
Actual
-$0.13
Surprise
+29.19%
Cellectis S.A. - ADR
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.27
Actual
-$0.22
Surprise
+20.89%
Entera Bio Ltd. Ordinary Shares
Report Date
Aug 07, 2026 For Q2 26
Estimate
-$0.08
Actual
-$0.14
Surprise
-71.57%
BioMarin Pharmaceuticals Inc
Report Date
Aug 06, 2026 For Q2 26
Estimate
$0.70
Actual
$1.20
Surprise
+71.04%
FAQ
What were Absci Corporation Common Stock's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Absci Corporation Common Stock reported EPS of -$0.19, beating estimates by 11.3%, and revenue of $215.00K, -86.4% below expectations.
How did the market react to Absci Corporation Common Stock's Q1 2026 earnings?
The stock price moved up 2.61%, changed from $5.75 before the earnings release to $5.90 the day after.
When is Absci Corporation Common Stock expected to report next?
The next earning report is scheduled for Aug 11, 2026.
What are the forecasts for Absci Corporation Common Stock's next earnings report?
Based on 9
analysts, Absci Corporation Common Stock is expected to report EPS of -$0.20 and revenue of $1.24M for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement